(NASDAQ: HBIO) Harvard Bioscience's forecast annual revenue growth rate of 2.92% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 3.9%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 21.28%.
Harvard Bioscience's revenue in 2026 is $87,808,000.On average, 4 Wall Street analysts forecast HBIO's revenue for 2026 to be $411,400,907, with the lowest HBIO revenue forecast at $394,375,287, and the highest HBIO revenue forecast at $424,456,918.
In 2027, HBIO is forecast to generate $437,403,674 in revenue, with the lowest revenue forecast at $412,220,322 and the highest revenue forecast at $458,872,344.